StockWatch
·
COSMO FIRST · Q2 FY27 · THE VERDICT

+51% Revenue, +111% PAT — But Core Profit Growth Is Half That

Reported earnings doubled, but ₹18 crore in non-recurring gains and ₹4.5 crore in consumer losses mask a more modest 11.5% organic margin. Specialty scaling is real; whether it justifies the 42% discount to all-time high depends on proof in H2.

Q2 FY27 resultsCOSMOFIRSTCosmo First Ltd10 Nov 2026 · 6 min read
Reported Revenue

₹1,388 Cr

+51% YoY

Reported EBITDA

₹177 Cr

+38% YoY (includes non-recurring)

Adjusted EBITDA

~₹159 Cr

ex ₹18 Cr net boost

Reported PAT

₹99 Cr

+111% YoY

The headline numbers are spectacular: revenue +51%, profit +111%, EBITDA +38% year-on-year. Management beat prior guidance on US films (35% vs 25–30%) and specialty acceleration (59% growth in specialty chemicals H1), debt is falling on schedule, and the Q&A showed confidence. But the quarter carried ₹24.8 crore in customs refunds and ₹7 crore in inventory losses—net ₹18 crore boost to EBITDA. Strip those out, and the organic margin shrinks to 11.5%. Add Cosmo Consumer's ₹4.5 crore EBITDA loss (from ₹4 crore of advertising spend) and brand-building drag, and the real operating picture becomes clearer: this quarter was a beat, but a messier one than the headline suggests.

Where the profit leverage came from

Q2 FY27 EBITDA bridge, ₹ Cr
-41.439.2119.8200.4177Reported-18Non-recurring boost159Adjusted (core)
Reported EBITDA includes ₹24.8 Cr customs refund less ₹7 Cr inventory loss. Adjusted margin 11.5% vs. reported 12.8%.
Management claims on the call vs. what holds up

Revenue +51% YoY; EBITDA +38%

₹1,388 Cr vs ₹918 Cr Q2 FY26. EBITDA ₹177 Cr vs ₹128 Cr. Figures accurate.

Supported

US films +35% growth, ahead of 25–30% prior guidance

35% volume growth in Q2 stated; exceeded prior target. Maintained customer base; won new wins when competitors exited. >$100M FY27 target credible.

Supported

Specialty chemicals H1 revenue ₹155 Cr, +59% growth

H1 specialty chemicals growth 59% confirmed in call. Absolute ₹155 Cr not in consolidated result; plausible from segment math.

Corroborated

Specialty films 20% volume growth H1; target 65–70% mix FY28

Specialty 60% of volume H1, growing 20% YoY. New coating line (16K tons) + barrier sheet (10K tons) in H2 pipeline. On track.

Supported

Net debt reduced ₹102 Cr in H1 despite ₹148 Cr working capital inflation

Sep 26 net debt ₹1,057 Cr vs Mar 26 ₹1,159 Cr = ₹102 Cr reduction. Working capital pressured by raw-material costs. Accurate.

Supported

Debt reduction ₹300–500 Cr over 2 years; <2x EBITDA within 12 months

Currently 1.9x EBITDA (Sep 26). H1 tracking well. Renewable power (₹25–30 Cr annual savings FY28) to accelerate pay-down.

On track

Cosmo Consumer to break-even after 2-year loss phase

Q2 loss ₹4.5 Cr (₹4 Cr ad spend). Management budgeting 2-year losses; no fixed break-even date or exit target disclosed.

Soft commitment

What changed on this call

Three material shifts from Q1 FY27: (1) Specialty chemical growth accelerated to 59% in H1, up from the 10% CAGR this vertical had historically tracked—a structural re-rating of scaling speed. (2) US films beat prior guidance (35% volume growth vs 25–30% target), and management raised confidence to >$100M revenue this FY with 8–10% capacity headroom available. (3) Cosmo Consumer losses became quantified and material—₹4.5 crore EBITDA loss in Q2, management expects 2-year loss phase during brand-building. This was not sized as clearly in prior calls. On the positive, debt reduction is on track (₹102 crore in H1 vs ₹300–500 Cr target over 2 years), and no guidance was withdrawn.

Bull-bear ledger
  • Specialty scaling accelerating: chemicals +59% H1, Plastech +73%, path to 65–70% FY28 real

  • US films beat guidance (35% vs 25–30%); >$100M FY27 target credible on customer wins

  • Debt reduction on track (₹102 Cr in H1 vs ₹300–500 Cr target over 2 years)

  • Management track record strong: 20% guidance beaten by 51% revenue, 25–30% beaten by 35% US growth

  • Reported Q2 profit includes ₹18 Cr non-recurring net boost (customs refund + inventory loss)

  • Cosmo Consumer EBITDA loss ₹4.5 Cr in Q2; expected 2 years, no fixed break-even target

  • Core EBITDA margin only 11.5% on organic basis; flat vs prior quarters

  • Raw-material volatility persists (West Asia); inventory timing risk acknowledged

  • FII ownership fell 108 bps year-on-year (3.49% → 2.41%); institutional skepticism evident

  • Stock 42% below all-time high; SMA-50 still above price (₹837 vs ₹825), valuation floor visible

Risks, ranked by holder concern

What could derail the specialty thesis and why it matters

Specialty margin expansion dependent on new product approvals (Korea/Japan, barrier sheet)

High

Core thesis is 65–70% specialty mix with higher per-kg margins (coating US$0.70–1.00 value-add). Customer approvals take 3–5 years; if delayed or rejected, capex ROI deteriorates and margin targets slip. H2 FY27 ramp execution will be first proof point.

Cosmo Consumer losses extend beyond 2-year timeline

High

Q2 loss ₹4.5 Cr from ad spend; break-even timeline is soft (no fixed date). If market adoption slower than expected, losses extend, pressuring group EBITDA and return on equity.

Raw-material volatility and inventory timing

Medium

Q2 included ₹7 Cr inventory loss due to raw-material timing. BOPP margin ₹29/kg Q2 vs ₹30/kg Q1. If commodity costs reverse sharply, write-downs or margin compression next quarter. West Asia crisis unpredictable.

Debt servicing if EBITDA growth slows or capex misses

Medium

Net debt ₹1,057 Cr at 1.9x EBITDA. If specialty capex ROI disappoints or EBITDA growth decelerates, covenant pressure. Current plan assumes ₹300–500 Cr debt reduction over 2 years (15%+ EBITDA CAGR required).

FII and institutional skepticism (flow headwind)

Medium

FII ownership down 108 basis points year-on-year. Stock down 42% from all-time high. Institutional capital hasn't bought the thesis yet. Continued selling could cap re-rating even if execution solid.

Zigly transaction clarity and consumer brand-building strategy

Low

Zigly growth 47% but transaction status vague ('exploring options, no timeline'). Consumer business 2-year loss phase lacks fixed exit targets. Lack of clarity limits investor confidence in long-term TAM assumptions.

What to watch next

Catalysts and execution milestones
  • 1 · H2 FY27 capex ramp: Coating line (16K tons) + barrier sheet (10K tons) commissioning

    First proof point on new capacity execution. If ramp on schedule and early customer approvals visible (even in small volumes), specialty thesis credibility rises. Margin profile critical—watch for ₹62+/kg specialty film sustained.

  • 2 · Q3 FY27 core EBITDA (ex non-recurring): Does organic margin stabilize or compress?

    Q2 benefited from customs refund and inventory reversals. If Q3 shows 11–12% core EBITDA margin, specialty thesis intact. If falls below 10%, questions about operating leverage.

  • 3 · Cosmo Consumer profitability path: Does ad spend moderation yield progress toward breakeven?

    Q2 loss ₹4.5 Cr from ₹4 Cr ad spend. If Q3–Q4 ad spend cuts in half and losses narrow, 2-year breakeven credible. If losses widen, consumer thesis at risk.

  • 4 · Korea/Japan specialty approvals: Any near-term (6–12 month) regulatory green-lights announced?

    3–5 year approval cycle is long. Early signals of Japan/Korea market entry timeline would validate international expansion and justify ₹100–110 Cr FY27 capex.

  • 5 · FII flows and re-entry: Do institutional investors stabilize or continue trimming?

    FII down 108 bps year-on-year. If institutional capital re-enters on specialty thesis, stock could re-rate toward SMA-50 (₹837) or higher. If selling persists, headwind remains.

How the street is positioned

The stock has been under pressure: ₹825 (pre-announcement) sits below SMA-50 (₹836.69) but above SMA-20 (₹779.73), in the middle of the 52-week range (₹561–₹996), and 42% below its all-time high. RSI at 55.8 signals NEUTRAL momentum—not oversold, not overbought. Volume is increasing. The real story is in the ownership data: FII holdings fell 108 basis points year-on-year (3.49% → 2.41%), while promoter stake remains locked at ~41% and DII flat at ~1.5%. Institutional capital is exiting, not entering. At a 42% drawdown from all-time high, the stock is priced for disappointment. Specialty scaling is the thesis that could change that, but it needs proof in the numbers: H2 capex execution, Q3 organic margin hold, and consumer losses narrowing as promised. For now, the street's skepticism is warranted: a Hold.

Cosmo First delivered a strong quarter on headline numbers, beat prior guidance, and is scaling specialty correctly. But profit quality is mixed—non-recurring items and consumer losses mask a more modest organic margin—and institutional investors are exiting. The debate is whether specialty scaling and debt reduction justify a re-entry at this valuation. Likely answer: not yet. The stock needs to prove it in the numbers, not just the strategy. Watch core EBITDA margin (target 11.5% to expand to 12–13% on mix), capex execution in H2 (proof of new capacity ROI), and whether consumer losses narrow as promised. The single number to track is adjusted EBITDA margin. If it expands to 12–13% on specialty mix shift and holds as new capacity ramps, the Hold becomes a Buy. For now, wait.

Informational and educational content only. Not investment advice.